Verona Pharma Announces US FDA Approval of Ohtuvayre™ …
Jun 26, 2024 · Ohtuvayre is the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Verona has evaluated nebulized Ohtuvayre in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment.
Ohtuvayre effective across key patient subgroups: ENHANCE trials
Oct 14, 2024 · Top-line results showed that Ohtuvaryre significantly improved lung function, lowered the rate of pulmonary exacerbations — periods of sudden lung symptom worsening — and tended to ease COPD symptoms relative to the placebo.
Verona Pharma Announces US FDA Approval of Ohtuvayre™ …
Jun 26, 2024 · Ohtuvayre is a first-in-class selective dual inhibitor of the enzymes phosphodiesterase 3 and phosphodiesterase 4 (“PDE3 and PDE4”) that combines bronchodilator and non-steroidal...
FDA Approves Ensifentrine for Maintenance Treatment of Adult
Jun 26, 2024 · The FDA has approved ensifentrine (Ohtuvayre; Verona Pharma) for the maintenance treatment of moderate to severe chronic obstructive pulmonary disease based on successful phase 3 ENHANCE trials...
FDA approves Ohtuvayre as maintenance treatment for COPD
Jun 27, 2024 · The FDA has approved the phosphodiesterase enzyme 3 and 4 inhibitor ensifentrine, now named Ohtuvayre, for treating adults with COPD, according to a manufacturer-issued press release.
US FDA New Drug Application Approval of Ohtuvayre™ …
SHANGHAI, June 27, 2024 /PRNewswire/ -- Nuance Pharma's global partner Verona Pharma plc (Nasdaq: VRNA), announces the US Food and Drug Administration ("FDA") approved Ohtuvayre (ensifentrine)...
Verona scores FDA approval for Ohtuvayre as COPD maintenance …
Jun 27, 2024 · The US Food and Drug Administration (FDA) has approved Verona Pharma’s Ohtuvayre (ensifentrine) as a maintenance treatment for chronic obstructive pulmonary disease (COPD) in adult patients.
Ohtuvayre - Verona Pharma
Discover Verona Pharma's innovative newly FDA approved treatment Ohtuvayre (ensifentrine). Learn more about its novel mechanism of action.
Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre …
Jun 27, 2024 · Ohtuvayre is the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule.
Ohtuvayre Approved for Maintenance Treatment of COPD
Jun 27, 2024 · The Food and Drug Administration (FDA) has approved Ohtuvayre ™ (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.